Background
The optimal timing of resuming direct oral anticoagulants (DOACs) after high-risk endoscopic procedures remains uncertain. Existing recommendations are largely based on expert opinion, resulting in substantial practice variability. Understanding clinician equipoise and patient preferences is essential to inform the design of randomized trials, including the proposed Resumption of Direct Oral Anticoagulants After High-Risk Endoscopy (RESUME) trial.
Methods We conducted parallel, cross-sectional surveys of practicing endoscopists and patients with atrial fibrillation using electronic questionnaires administered via Qualtrics. The endoscopist survey, distributed through the American Society for Gastrointestinal Endoscopy, assessed practice patterns, acceptability of early (postoperative day [POD] +1), intermediate (POD +3), and late (POD +5) resumption strategies, and perceptions of clinical equipoise. The patient survey, distributed through two advocacy organizations, evaluated awareness of evidence gaps and prioritization of bleeding versus thromboembolic risk.
Results A total of 201 endoscopists and 477 patients (92.5% taking a DOAC) were included. Endoscopists demonstrated wide variability in preferred timing of DOAC resumption after a standardized high-risk mucosal resection vignette, ranging from same-day resumption to delays beyond five days. POD +2 was the most commonly selected strategy, and most respondents rated more than one proposed RESUME trial arm as acceptable. Nearly all endoscopists (98.9%) rated a randomized trial to determine optimal timing as important. Patient preferences regarding bleeding versus stroke risk were heterogeneous and symmetrically distributed around the neutral response on a five-point ordinal scale. Preferences did not differ by prior stroke or transient ischemic attack, prior major bleeding, age, sex, or geographic region. More than half of patients reported confidence that clear guidance exists regarding DOAC resumption, despite the absence of high-quality randomized evidence informing postprocedural timing.
Conclusions Both clinicians and patients demonstrate substantial variability and clinical uncertainty regarding optimal timing of DOAC resumption after high-risk endoscopy, supporting the ethical justification, feasibility, and relevance of the proposed RESUME trial.
Competing Interest Statement
The authors have declared no competing interest.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Date:10/24/2025 Project Title:Resumption of Direct Oral Anticoagulants After High-Risk Endoscopy (RESUME): Patient Perspectives Survey PRO ID:PRO00057092 IRB Registration Date: 10/24/2025 The MCW Institutional Review Board #5 has determined the above-referenced submission meets the criteria for registration in accordance with the MCW IRB Policy: Registration Projects: Human Subject Research Projects which Qualify for Flex Review, Registration Category 2. This determination extends to the following institutions: Medical College of Wisconsin - Milwaukee Campus The items listed below were submitted and reviewed with this submission. Research must be conducted in accordance with the IRB's determination as described in the documents listed below and institutional policy: Survey Informational letter and consent Given that the current project involves direct contact with subjects, an informed consent process utilizing an informational letter has been approved and is effective 10/24/2025. The IRB has determined this project does not require approval of a waiver of HIPAA authorization or a HIPAA authorization as set forth in 45 CFR 164.514(e) as the project will not access or collect PHI.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Author Roles Study design: All authors
Statistical analysis: ZLS, DMS
Manuscript writing and edits: All authors
Final approval of manuscript: All authors
Disclosures Dr. Smith is a member of the ASGE Research Committee but was recused from the review of the survey application. None of the authors have any relevant conflicts of interest to disclose.
Funding The access fee for the ASGE membership distribution was funded internally by the Medical College of Wisconsin Division of Gastroenterology and Hepatology. There was no additional funding for this study.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
Abbreviations
- DOAC
- Direct Oral Anticoagulant
- GI
- Gastrointestinal
- POD
- Postoperative Day
- EMR
- Endoscopic Mucosal Resection
- AF
- Atrial Fibrillation
- ACG
- American College of Gastroenterology
- CAG
- Canadian Association of Gastroenterology
- JGES
- Japan Gastrointestinal Endoscopy Society
- ASGE
- American Society for Gastrointestinal Endoscopy
- ERCP
- Endoscopic Retrograde Cholangiopancreatography
- ESD
- Endoscopic Submucosal Dissection
- US
- United States
- RESUME
- Resumption of Direct Oral Anticoagulants After High-Risk Endoscopy
- IRB
- Institutional Review Board
- MCW
- Medical College of Wisconsin
